Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Equity (2016 - 2025)

Coherus Oncology's Return on Equity history spans 12 years, with the latest figure at 4.72% for Q4 2025.

  • For Q4 2025, Return on Equity rose 694.0% year-over-year to 4.72%; the TTM value through Dec 2025 reached 4.72%, up 694.0%, while the annual FY2025 figure was 9.89%, 840.0% down from the prior year.
  • Return on Equity for Q4 2025 was 4.72% at Coherus Oncology, up from 3.25% in the prior quarter.
  • Across five years, Return on Equity topped out at 45.79% in Q2 2022 and bottomed at 11.46% in Q2 2025.
  • The 5-year median for Return on Equity is 0.23% (2024), against an average of 1.88%.
  • The largest annual shift saw Return on Equity skyrocketed 4789bps in 2022 before it crashed -4436bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 2.51% in 2021, then soared by 199bps to 2.49% in 2022, then plummeted by -42bps to 1.45% in 2023, then plummeted by -252bps to 2.22% in 2024, then skyrocketed by 313bps to 4.72% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Return on Equity are 4.72% (Q4 2025), 3.25% (Q3 2025), and 11.46% (Q2 2025).